Endocannabinoids and related N-acylethanolamines in the control of appetite and energy metabolism: Emergence of new molecular players

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 10, Issue 6, 2007, Pages 735-744

  Lambert, Didier M ^a   Muccioli, Giulio G ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

2 arachidonoylglycerol; Anandamide; CB1 cannabinoid receptor; GPR 119; Oleoylethanolamide; Peroxisome proliferator activated receptor

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ALPHA INTERMEDIN; AMPHETAMINE; ANANDAMIDE; ANOREXIGENIC AGENT; CANNABINOID 1 RECEPTOR; COCAINE; CORTICOTROPIN RELEASING FACTOR; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; G PROTEIN COUPLED RECEPTOR; GHRELIN; GPR 119 RECEPTOR; LEPTIN; N OLEOYLETHANOLAMINE; NEUROPEPTIDE Y; OPIATE; OREXIN; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; RIMONABANT; UNCLASSIFIED DRUG;

APPETITE; BINDING SITE; ENERGY EXPENDITURE; ENERGY METABOLISM; FOOD INTAKE; HUMAN; METABOLIC SYNDROME X; MOLECULAR MECHANICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW;

APPETITE REGULATION; ENDOCANNABINOIDS; ENERGY INTAKE; ENERGY METABOLISM; ETHANOLAMINES; HUMANS; LIPID METABOLISM; OBESITY; SIGNAL TRANSDUCTION;

EID: 37349000968     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e3282f00061     Document Type: Review

References (114)

1. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258:1946-1949.
2. Lambert DM, Fowler CJ. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem 2005; 48:5059-5087.
3. Kogan NM, Mechoulam R. The chemistry of endocannabinoids. J Endocrinol Invest 2006; 29:3-14.
4. Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 2007; 18:27-37. A comprehensive review on the endocannabinoid actions at both central and peripheral levels. Includes a description of the outcome of the clinical trials on rimonabant, the CB1 cannabinoid antagonist.
5. Okamoto Y, Morishita J, Tsuboi K, et al. Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 2004; 279:5298-5305.
6. 2+-independent phosphatidylethanolamine N-acyltransferase generating the anandamide precursor and its congeners. J Biol Chem 2007; 282:3614-3623. A very nice paper describing the cloning and characterization of an N-acyltransferase activity, the enzyme responsible for the first step in anandamide synthesis.
7. Leung D, Saghatelian A, Simon GM, Cravatt BF. Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 2006; 45:4720-4726. Proof of concept that NAPE phospholipase D is not the main enzyme involved in anandamide biosynthesis.
8. Simon GM, Cravatt BF. Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for a/b-hydrolase 4 in this pathway. J Biol Chem 2006; 281:26465-26472. A new pathway for the synthesis of N-acylethanolamines.
9. Liu J, Wang L, Harvey-White J, et al. A biosynthetic pathway for anandamide. Proc Natl Acad Sci USA 2006; 103:13345-13350. A new pathway for the synthesis of N-acylethanolamines.
10. Bisogno T, Howell F, Williams G, et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 2003; 163:463-468.
11. Bisogno T, Ligresti A, Di Marzo V. The endocannabinoid signalling system: biochemical aspects. Pharmacol Biochem Behav 2005; 81:224-238.
12. Gonthier MP, Hoareau L, Festy F, et al. Identification of endocannabinoids and related compounds in human fat cells. Obesity 2007; 15:837-845. Identification and quantification of the endocannabinoids and related compounds in human adipocytes.
13. Moore SA, Nomikos GG, Dickason-Chesterfield AK, et al. Identification of a high-affinity binding site involved in the transport of endocannabinoids. Proc Natl Acad Sci USA 2005; 102:17852-17857.
14. Alexander JP, Cravatt BF. The Putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. J Am Chem Soc 2006; 128:9699-9704.
15. Ortar G, Cascio MG, Moriello AS, Camalli M, Morera E, Nalli M, Di Marzo V. Carbamoyl tetrazoles as inhibitors of endocannabinoid inactivation: a critical revisitation. Eur J Med Chem 2007; 19 March [Epub ahead of print].
16. Cravatt BF, Giang DK, Mayfield SP, et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996; 384:83-87.
17. Karlsson M, Contreras JA, Hellman U, et al. cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase: evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. J Biol Chem 1997; 272:27218-27223.
18. Dinh TP, Carpenter D, Leslie FM, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 2002; 99:10819-10824.
19. Tsuboi K, Sun YX, Okamoto Y, et al. Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J Biol Chem 2005; 280:11082-11092.
20. Wei BQ, Mikkelsen TS, McKinney MK, et al. A second fatty acid amide hydrolase with variable distribution among placental mammals. J Biol Chem 2006; 281:36569-36578. This paper describes a second FAAH which has different substrate preferences and localization compared with the first FAAH.
21. Muccioli GG, Xu C, Cudaback E, et al. Identification of a novel endocannabinoid-hydrolyzing enzyme expressed by microglial cells. J Neurosci 2007; 27:2883-2889.
22. Dinh TP, Kathuria S, Piomelli D. RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol Pharmacol 2004; 66:1260-1264.
23. Vandevoorde S, Saha B, Mahadevan A, et al. Influence of the degree of unsaturation of the acyl side chain upon the interaction of analogues of 1-arachidonoylglycerol with monoacylglycerol lipase and fatty acid amide hydrolase. Biochem Biophys Res Commun 2005; 337:104-109.
24. Maccarrone M, Gasperi V, Fezza F, et al. Differential regulation of fatty acid amide hydrolase promoter in human immune cells and neuronal cells by leptin and progesterone. Eur J Biochem 2004; 271:4666-4676.
25. Engeli S, Bohnke J, Feldpausch M, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005; 54:2838-2843.
26. Bluher M, Engeli S, Kloting N, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006; 55:3053-3060. Very interesting study demonstrating the variations in the endocannabinoid tone found in obese humans.
27. Sipe JC, Chiang K, Gerber AL, et al. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci USA 2002; 99:8394-8399.
28. Sipe JC, Waalen J, Gerber A, Beutler E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes 2005; 29:755-759.
29. Jensen DP, Andreasen CH, Andersen MK, et al. The functional Pro129Thr variant of the FAAH gene is not associated with various fat accumulation phenotypes in a population-based cohort of 5801 whites. J Mol Med 2007; 85:445-449.
30. Aberle J, Fedderwitz I, Klages N, et al. Genetic variation in two proteins of the endocannabinoid system and their influence on body mass index and metabolism under low fat diet. Horm Metab Res 2007; 39:395-397. The influence of FAAH polymorphism on the effect of a 6-week diet is reported. Carriers of the P129T mutation in FAAH had a significantly greater decrease in triglycerides and total cholesterol compared with wild type.
31. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002; 136:550-557.
32. Higgs S, Williams CM, Kirkham TC. Cannabinoid influences on palatability: microstructural analysis of sucrose drinking after D9-tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR141716. Psychopharmacology 2003; 165:370-377.
33. Jamshidi N, Taylor DA. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 2001; 134: 1151-1154.
34. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410:822-825.
35. Ravinet Trillou C, Delgorge C, Menet C, et al. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obesity 2004; 28:640-648.
36. Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112:423-431.
37. Ravinet-Trillou C, Arnone M, Delgorge C, et al. Antiobesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003; 284:R345-R353.
38. Hildebrandt AL, Kelly-Sullivan DM, Black SC. Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. Eur J Pharmacol 2003; 462:125-132.
39. Shearman LP, Rosko KM, Fleischer R, et al. Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav Pharmacol 2003; 14:573-582.
40. Werner NA, Koch JE. Effects of the cannabinoid antagonists AM281 and AM630 on deprivation-induced intake in Lewis rats. Brain Res 2003; 967:290-292.
41. Lin LS, Lanza TJ Jr, Jewell JP, et al. Discovery of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl] -2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. J Med Chem 2006; 49:7584-7587.
42. Pavon FJ, Bilbao A, Hernandez-Folgado L, et al. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole: LH 21. Neuropharmacology 2006; 51:358-366.
43. Freedland CS, Poston JS, Porrino LJ. Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding. Pharmacol Biochem Behav 2000; 67:265-270.
44. McLaughlin PJ, Winston K, Swezey L, et al. The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behav Pharmacol 2003; 14:583-588.
45. Colombo G, Agabio R, Diaz G, et al. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 1998; 63:L113-L117.
46. Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63:908-914.
47. Gary-Bobo M, Elachouri G, Gallas JF, et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 2007; 46:122-129. Study on the effects of the CB1 blocker rimonabant on liver metabolism. Rimonabant was shown to exert a hepatoprotective effect in obese animals.
48. Poirier B, Bidouard JP, Cadrouvele C, et al. The antiobesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obesity Metab 2005; 7:65-72.
49. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365:1389-1397.
50. Despres JP, Golay A, Sjoestroem L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New Engl J Med 2005; 353:2121-2134.
51. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al., for the RIO. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295:761-775.
52. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; 368:1660-1672.
53. Henness S, Robinson DM, Lyseng-Williamson KA. Rimonabant. Drugs 2006; 66:2109-2119.
54. Bifulco M, Grimaldi C, Gazzerro P, et al. Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects. Mol Pharmacol 2007; 71:1445-1456.
55. Patel PN, Pathak R. Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity. Am J Health Syst Pharm 2007; 64:481-489.
56. Lafontan M, Piazza PV, Girard J. Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients. Diabetes Metab 2007; 33:85-95. Interesting review summarizing the recent findings on the effects of blocking the CB1 receptor in patients with diabetes.
57. Matias I, Vergoni AV, Petrosino S, et al. Regulation of hypothalamic endocannabinoidlevels byneuropeptides andhormones involvedin foodintake and metabolism: insulin and melanocortins. Neuropharmacology (in press).
58. Gamber KM, Macarthur H, Westfall TC. Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus. Neuropharmacology 2005; 49:646-652.
59. Cani PD, Montoya ML, Neyrinck AM, et al. Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide. Br J Nutr 2004; 92:757-761.
60. Tucci SA, Rogers EK, Korbonits M, Kirkham TC. The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Br J Pharmacol 2004; 143:520-523.
61. Rigamonti AE, Giordani C, Bonomo SM, et al. Early tolerance to the hypophagic effect of the cannabinoid receptor antagonist SR141716 does not impede blockade of an orexigenic stimulus. Eur J Pharmacol 2006; 542:116-120.
62. Hilairet S, Bouaboula M, Carriere D, et al. Hypersensitization of the orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific cb1 antagonist, SR141716. J Biol Chem 2003; 278:23731-23737.
63. Ellis J, Pediani JD, Canals M, et al. Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J Biol Chem 2006; 281:38812-38824.
64. Huang H, Acuna-Goycolea C, Li Y, et al. Cannabinoids excite hypothalamic melanin-concentrating hormone but inhibit hypocretin/orexin neurons: implications for cannabinoid actions on food intake and cognitive arousal. J Neurosci 2007; 27:4870-4881.
65. Kirkham TC, Williams CM. Synergistic effects of opioid and cannabinoid antagonists on food intake. Psychopharmacology 2001; 153:267-270.
66. Solinas M, Goldberg SR. Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems. Neuropsychopharmacology 2005; 30:2035-2045.
67. Hermann H, Lutz B. Coexpression of the cannabinoid receptor type 1 with the corticotropin-releasing hormone receptor type 1 in distinct regions of the adult mouse forebrain. Neurosci Lett 2005; 375:13-18.
68. Verty AN, McFarlane JR, McGregor IS, Mallet PE. Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. Endocrinology 2004; 145:3224-3231.
69. Osei-Hyiaman D, DePetrillo M, Harvey-White J, et al. Cocaine- and amphetamine-related transcript is involved in the orexigenic effect of endogenous anandamide. Neuroendocrinology 2005; 81:273-282.
70. Spoto B, Fezza F, Parlongo G, et al. Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol. Biochimie 2006; 88:1889-1897. Further proof of the presence of an active endocannabinoid system in adipose tissue in humans.
71. Gasperi V, Fezza F, Pasquariello N, et al. Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell Mol Life Sci 2007; 64:219-229.
72. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115:1298-1305.
73. Gomez R, Navarro M, Ferrer B, et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002; 22:9612-9617.
74. Bermudez-Siva FJ, Serrano A, Diaz-Molina FJ, et al. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur J Pharmacol 2006; 531:282-284.
75. Juan-Pico P, Fuentes E, Bermudez-Silva FJ, et al. Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium 2006; 39:155-162.
76. Bermudez-Silva FJ, Sanchez-Vera I, Suarez J, et al. Role of cannabinoid CB2 receptors in glucose homeostasis in rats. Eur J Pharmacol 2007; 565:207-211.
77. Matias I, Gonthier MP, Orlando P, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006; 91:3171-3180.
78. Pagotto U, Marsicano G, Cota D, et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006; 27:73-100. Comprehensive recent review on the endocannabinoid role in regulating energy metabolism.
79. 1 receptor activation.
80. Yan ZC, Liu DY, Zhang LL, et al. Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta. Biochem Biophys Res Commun 2007; 354:427-433.
81. Matias I, Di Marzo V. Endocannabinoid synthesis and degradation, and their regulation in the framework of energy balance. J Endocrinol Invest 2006; 29:15-26.
82. Lambert DM, DiPaolo FG, Sonveaux P, et al. Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB2 cannabinoid, as potential ligands for the cannabinoid receptors. Biochim Biophys Acta 1999; 1440:266-274.
83. Jonsson KO, Vandevoorde S, Lambert DM, et al. Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. Br J Pharmacol 2001; 133:1263-1275.
84. Cravatt BF, Demarest K, Patricelli MP, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 2001; 98:9371-9376.
85. Rodriguez de Fonseca F, Navarro M, Gomez R, et al. An anorexic lipid mediator regulated by feeding. Nature 2001; 414:209-212.
86. Fu J, Astarita G, Gaetani S, et al. Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. J Biol Chem 2007; 282:1518-1528. N-oleoylethanolamine controls food intake by acting in the gastrointestinal tract, and food intake regulates N-oleoylethanolamine levels through regulation of the enzymes involved in its metabolism.
87. Petersen G, Sorensen C, Schmid PC, et al. Intestinal levels of anandamide and oleoylethanolamide in food-deprived rats are regulated through their precursors. Biochim Biophys Acta 2006; 1761:143-150. The levels of anandamide and N-oleoylethanolamine are inversely regulated by food intake.
88. Oveisi F, Gaetani S, Eng KT, Piomelli D. Oleoylethanolamide inhibits food intake in free-feeding rats after oral administration. Pharmacol Res 2004; 49:461-466.
89. Nielsen MJ, Petersen G, Astrup A, Hansen HS. Food intake is inhibited by oral oleoylethanolamide. J Lipid Res 2004; 45:1027-1029.
90. Fu J, Gaetani S, Oveisi F, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α. Nature 2003; 425:90-93.
91. Guzman M, Lo Verme J, Fu J, et al. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor a (PPAR-α). J Biol Chem 2004; 279:27849-27854.
92. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005; 54:2460-2470.
93. Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 2005; 26:244-251.
94. Fievet C, Fruchart JC, Staels B. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr Opin Pharmacol 2006; 6:606-614.
95. Michalik L, Auwerx J, Berger JP, et al. International Union of Pharmacology. LXI: Peroxisome proliferator-activated receptors. Pharmacol Rev 2006; 58:726-741.
96. Backes JM, Gibson CA, Ruisinger JF, Moriarty PM. Fibrates: what have we learned in the past 40 years? Pharmacotherapy 2007; 27:412-424.
97. Sun Y, Alexander SP, Kendall DA, Bennett AJ. Cannabinoids and PPARalpha signalling. Biochem Soc Trans 2006; 34:1095-1097.
98. Bouaboula M, Hilairet S, Marchand J, et al. Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur J Pharmacol 2005; 517:174-181.
99. O'Sullivan SE, Tarling EJ, Bennett AJ, et al. Novel time-dependent vascular actions of Delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma. Biochem Biophys Res Commun 2005; 337:824-831.
100. O'Sullivan SE, Kendall DA, Randall MD. Further characterization of the time-dependent vascular effects of delta9-tetrahydrocannabinol. J Pharmacol Exp Ther 2006; 317:428-438.
101. 1 receptor antagonists and oleoylethanolamide-like derivatives.
102. Terrazzino S, Berto F, Dalle CM, et al. Stearoylethanolamide exerts anorexic effects in mice via down-regulation of liver stearoyl-coenzyme A desaturase-1 mRNA expression. FASEB J 2004; 18:1580-1582.
103. Yang Y, Chen M, Loux TJ, Harmon CM. Regulation of FAT/CD36 mRNA gene expression by long chain fatty acids in the differentiated 3T3-L1 cells. Pediatr Surg Int 2007; 23:675-683.
104. Soga T, Ohishi T, Matsui T, et al. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun 2005; 326:744-751.
105. Overton HA, Babbs AJ, Doel SM, et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 2006; 3:167-175. Very important paper suggesting that oleoylethanolamide possesses drugable molecular targets besides PPARα. Two synthetic ligands that activate GPR119 are also described.
106. Chu ZL, Jones RM, He H, et al. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 2007; 148:2601-2609. GPR119 is expressed in the pancreas where it can regulate glyceamia. This paper suggests that the receptor could be an interesting target for treating patients with diabetes.
107. Cano C, Pavon J, Serrano A, et al. Novel sulfamide analogs of oleoylethanolamide showing in vivo satiety inducing actions and PPARalpha activation. J Med Chem 2007; 50:389-393.
108. Astarita G, Di Giacomo B, Gaetani S, et al. Pharmacological characterization of hydrolysis-resistant analogs of oleoylethanolamide with potent anorexiant properties. J Pharmacol Exp Ther 2006; 318:563-570. Describes the pharmacological properties of N-(S)-1-hydroxypropan-2-yl)oleamide, a stable analogue of oleoylethanolamide that activates PPARa and regulates feeding in rodents.
109. Sakamoto Y, Inoue H, Kawakami S, et al. Expression and distribution of Gpr119 in the pancreatic islets of mice and rats: predominant localization in pancreatic polypeptide-secreting PP-cells. Biochem Biophys Res Commun 2006; 351:474-480.
110. Fegley D, Gaetani S, Duranti A, et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 2005; 313:352-358.
111. Hansen HS, Petersen G, Artmann A, Larsen PJ. Inhibitors of anorexic lipid hydrolysis for the treatment of eating disorders. Int. Pat. Appl. WO200700 6319; 2007.
112. Muccioli GG, Lambert DM. Latest advances in cannabinoid receptor antagonists and inverse agonists. Exp Opinion Ther Patents 2006; 16: 1405-1423.
113. Cha DR, Zhang X, Zhang Y, et al. PPAR {alpha}/{gamma} dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice. Diabetes 2007; 29 May [Epub ahead of print].
114. Bajaj M, Suraamornkul S, Hardies LJ, et al. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia 2007; 50:1723-1731.